Renagel®: Reducing serum pkosphorus in haemodialysis patients

Hospital Medicine

Volumn 61, Issue 9, 2000, Pages 622-627

  Burke, Steven K ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE; POLYAMINE; SEVELAMER;

BLOOD; CLINICAL TRIAL; GEL; HUMAN; MICROCAPSULE; RENAL REPLACEMENT THERAPY; REVIEW;

CAPSULES; CLINICAL TRIALS; GELS; HUMANS; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 0034265781     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2000.61.9.1419     Document Type: Article

References (24)

1. Bleyer AJ, Burke SK, Dillon M et al (1999) Calcium-tree phosphate binder RenaGel® [sevelamer hydrochloride] lowers serum phosphorus in hemodialysis patients. Am J Kidney Dis 33: 694-701
2. Block GA, Hubcrt-Shearon TE, Levin N W et al (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidnev Dix 31: 607-17
3. Braun J. Oldendorf M. Moshage W et al (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialvsis patients. Am J Kidney Dis 27:394-401
4. Blumenkrantz MJ. Kopple JD. Moran JK et al (1982) Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney lut 21: 849-61
5. Burke SK, Slatopolsky EA, Goldberg DI (1997) RenagelR, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephml Dial Transplant 12: 1640-4
6. Chertow GM. Burke SK, Lazarus JM et al (1997) Poly[allylamine Hydrochloride] (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphataemia in chronic renal failure. Am J Kidney Dis 29: 66-71
7. Chertow GM, Burke SK, Dillon MA et al ( 1999a) Long-term effects of scvelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephml Dial Transplant 14: 2907-14
8. Chertow GM, Dillon M. Burke SK et al (1999b) A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphataemia and hyperparathyroidism in hemodialysis patients. Clin Nephml 51: 18-26
9. Collins A. Hao W, Dalleska F. Ebben J (1999) Patients on Renagel phosphate binder have lower associated hospitalization risk. J Am Soc Nephml 10: 607 A
10. Combe C, Aparicio M (1994) Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46: 1381-6
11. Dclmez JA, Slatopolsky E (1992) Hypcrphosphataemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Ois 19: 303-17
12. Feinfeld DA, Sherwood LM (1988) Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidnev Int 33: 1049-58
13. Goldberg Dl. Dillon MA, Slatopolsky EA et al ( 1998) Effect of RenaGel®, a non-absorbed, calcium- and aluminiumfree phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephml Dial Transplant 13: 2303-10
14. Goodman WG, Goldin J, Kuizon BD et al (2000) Coronaryartery calcification in young adults with end-stage renal disease who arc undergoing dialysis. ,V Engl J Med 342(20): 1478-83
15. Guérin AP, London GM, Marchais SJ et al (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephml Dial Transplant 15: 1014-21
16. Hsu CH (1997) Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidnev Dis 29: 641-9
17. Kates DM, Andress DL (1996) Control of hyperphosphataemia in renal failure: role of aluminium. Semin Dialvsis 9: 310-15
18. Malluche HH, Monier-Faugere MC (1999) Understanding and managing hyperphosphataemia in patients with chronic renal disease. Clin Nephrol 52: 267-77
19. Pastan S. Bailey J (1998) Dialysis therapy. .V EnglJ Metl 338: 1428-37
20. Ribeiro S, Ramos A, Brandao A et al (1998) Cardiac valve-calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-40
21. Rosenbaum DP, Holmes-Farley SR. Mandeville WH et al ( 1997) Effect of RenaGel. a non-absorbable. cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephml Dial Transplant 12(5): 961-4
22. Rostand SG. Sanders C. Kirk KA et al (1988) Myocardial calcification and cardiac dysfunction in chronic renal failure. Am.IMed85: 651-7
23. Schwarz U Buzcllo M, Ritz E et al (2000) Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218 23
24. Slatopolsky EA. Burke SK. Dillon MA et al (1999) RenaGel 'S. a nonabsorbcd calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55: 299-307